Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.86 USD
Change Today +0.299 / 3.49%
Volume 26.9K
ADMA On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 5:20 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

adma biologics inc (ADMA) Snapshot

Open
$8.87
Previous Close
$8.56
Day High
$8.99
Day Low
$8.65
52 Week High
12/3/14 - $14.00
52 Week Low
05/8/15 - $7.51
Market Cap
94.8M
Average Volume 10 Days
12.5K
EPS TTM
$-1.54
Shares Outstanding
10.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ADMA BIOLOGICS INC (ADMA)

Related News

No related news articles were found.

adma biologics inc (ADMA) Related Businessweek News

No Related Businessweek News Found

adma biologics inc (ADMA) Details

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market plasma-based biologics for the treatment and prevention of certain infectious diseases. Its lead product candidate is RI-002, which is in Phase III clinical trial intended for the treatment of primary immune deficiency disease. RI-002 is an injectable immune globulin derived from human plasma enriched with high levels of naturally occurring polyclonal antibodies, as well as high levels of antibodies targeted to respiratory syncytial virus. The company also operates ADMA BioCenters, which are plasma collection centers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

60 Employees
Last Reported Date: 03/9/15
Founded in 2004

adma biologics inc (ADMA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $572.6K
Chief Financial Officer and Vice President
Total Annual Compensation: $398.1K
Chief Scientific & Medical Officer and Execut...
Total Annual Compensation: $377.0K
Compensation as of Fiscal Year 2014.

adma biologics inc (ADMA) Key Developments

ADMA Biologics Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

ADMA Biologics announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company announced total revenues of $1,503,106 compared to $1,560,559 for the same period a year ago. Loss from operations was $3,202,337 compared to $5,683,986 for the same period a year ago. Net loss was $3,605,535 compared to $5,903,872 for the same period a year ago. Net loss per common share, basic and diluted was $0.37 compared to $0.64 for the same period a year ago. The decreased quarter-over-quarter net loss was primarily attributed to lower research and development expenses of $1.4 million during the first quarter ended March 31, 2015, compared to $4.3 million during the first quarter ended March 31, 2014, as a result of completing the company’s fully enrolled Phase III clinical study during the fourth quarter 2014 and the completion of manufacturing of the company’s clinical drug product supply during the first quarter of 2014. The decreased net loss was offset by an increase of general and administrative costs, which were $1.3 million for the first quarter ended March 31, 2015 compared to $1.1 million during the first quarter ended March 31, 2014.

ADMA Biologics Announces Data to be Presented at the Clinical Immunology Society 2015 Annual Meeting

ADMA Biologics, Inc. announced its poster titled 'Analysis of Specific Antibody Levels in PIDD Patients Enrolled in a Pivotal Trial with an IVIG Containing High Titer Neutralizing Antibody to RSV', will be presented at the upcoming Clinical Immunology Society 2015 Annual Meeting, being held April 9-12, 2015 in Houston, Texas. ADMA will present data on the pharmacokinetic component of the pivotal Phase III trial and on the increases observed in the antibody titers to RSV and other pathogens in the patients infused with RI-002.

ADMA Biologics, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 09:00 AM

ADMA Biologics, Inc. Presents at Marcum Microcap Conference 2015, May-28-2015 09:00 AM. Venue: Grand Hyatt New York, Park Avenue at Grand Central, New York, NY 10017, United States. Speakers: Adam S. Grossmann, Founder, Chief Executive Officer, President and Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADMA:US $8.86 USD +0.299

ADMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADMA.
View Industry Companies
 

Industry Analysis

ADMA

Industry Average

Valuation ADMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.4x
Price/Book 6.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADMA BIOLOGICS INC, please visit www.admabiologics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.